Evidence map›Paper›PMID 40026632›Full record

ReviewMaterials today. Bio2025

3D bioprinting technology innovation in female reproductive system.

Siyao Chen, Tongxin Wang, Jiaqi Chen, Mingxing Sui, Luyao Wang, Xueyu Zhao, Jianqiao Sun, Yingli Lu

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. 3D bioprinting innovations: a new frontier in breast cancer research.Medical oncology (Northwood, London, England) · 2025
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siyao ChenDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, 130041, PR China.
Tongxin WangChanghai Hospital, Shanghai, 200433, PR China.
Jiaqi ChenDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, 130041, PR China.
Mingxing SuiDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, 130041, PR China.
Luyao WangDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, 130041, PR China.
Xueyu ZhaoDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, 130041, PR China.
Jianqiao SunReproductive Clinical Science, Macon & Joan Brock Virginia Health Sciences, Old Dominion University, Norfolk, VA, 23507, USA.
Yingli LuDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, 130041, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several diseases affect the female reproductive system, and both disease factors and treatments impact its integrity and function. Consequently, understanding the mechanisms of disease occurrence and exploring treatment methods are key research focuses in obstetrics and gynecology. However, constructing accurate disease models requires a microenvironment closely resembling the human body, and current animal models and 2D in vitro cell models fall short in this regard. Thus, innovative in vitro female reproductive system models are urgently needed. Additionally, female reproductive system diseases often cause tissue loss, yet effective tissue repair and regeneration have long been a bottleneck in the medical field. 3D bioprinting offers a solution by enabling the construction of implants with tissue repair and regeneration capabilities, promoting cell adhesion, extension, and proliferation. This helps maintain the long-term efficacy of bioactive implants and achieves both structural and functional repair of the reproductive system. By combining live cells with biomaterials, 3D bioprinting can create in vitro 3D biomimetic cellular models, facilitating in-depth studies of cell-cell and cell-extracellular microenvironment interactions, which enhances our understanding of reproductive system diseases and supports disease-specific drug screening. This article reviews 3D bioprinting methods and materials applicable to the female reproductive system, discussing their advantages and limitations to aid in selecting optimal 3D bioprinting strategies. We also summarize and critically evaluate recent advancements in 3D bioprinting applications for tissue regeneration and in vitro disease models and address the prospects and challenges for translating 3D bioprinting technology into clinical applications within the female reproductive system.

Indexed as

3D bioprintingFemale reproductive systemFemale reproductive system tumorsRegenerative medicine

Identifiers

PMID40026632
PMCPMC11870202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.